Skip to content

Source filing unavailable

Q2 2023 · —
Revenue—
Net Income-$5.52Mno prior Q2 2022 on fileN/M vs Q1 2023
EPS Diluted-$3.88no prior Q2 2022 on fileno prior Q1 2023 on file
Operating Income-$5,584,419—

What the release said

No earnings release is on file for this quarter. Its figures came with the 10-Q.

Same quarter

no prior Q2 2022 on file

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Actuate Therapeutics, Inc. · CIK 1652935 · Engraved from SEC EDGAR